Scholars@Duke

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Publication ,  Journal Article
Mesa, R; Jamieson, C; Bhatia, R; Deininger, MW; Gerds, AT; Gojo, I; Gotlib, J; Gundabolu, K; Hobbs, G; Klisovic, RB; Kropf, P; Mohan, SR ...
Published in: J Natl Compr Canc Netw
December 2016
Published version (DOI) Link to item

Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagnosis and the management of patients with MPNs have evolved since the identification of mutations that activate the JAK pathway (JAK2, CALR, and MPL mutations) and the development of targeted therapies has resulted in significant improvements in disease-related symptoms and quality of life. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnostic workup of MPN (MF, PV, and ET), risk stratification, treatment, and supportive care strategies for the management of MF.

Duke Scholars

Lindsay Anne Magura Rein
Author Lindsay Anne Magura Rein Medicine, Hematologic Malignancies and Cellular Therapy

Published In

J Natl Compr Canc Netw

DOI

10.6004/jnccn.2016.0169

EISSN

1540-1413

Publication Date

December 2016

Volume

14

Issue

12

Start / End Page

1572 / 1611

Location

United States

Related Subject Headings

  • Thrombocythemia, Essential
  • Signal Transduction
  • Risk Assessment
  • Receptors, Thrombopoietin
  • Quality of Life
  • Primary Myelofibrosis
  • Prevalence
  • Polycythemia Vera
  • Philadelphia Chromosome
  • Oncology & Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mesa, R., Jamieson, C., Bhatia, R., Deininger, M. W., Gerds, A. T., Gojo, I., … Sundar, H. (2016). Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 14(12), 1572–1611. https://doi.org/10.6004/jnccn.2016.0169
Mesa, Ruben, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Aaron T. Gerds, Ivana Gojo, Jason Gotlib, et al. “Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 14, no. 12 (December 2016): 1572–1611. https://doi.org/10.6004/jnccn.2016.0169.
Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, et al. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Dec;14(12):1572–611.
Mesa, Ruben, et al. “Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw, vol. 14, no. 12, Dec. 2016, pp. 1572–611. Pubmed, doi:10.6004/jnccn.2016.0169.
Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, Pollyea DA, Rampal R, Rein LAM, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Dec;14(12):1572–1611.

Published In

J Natl Compr Canc Netw

DOI

10.6004/jnccn.2016.0169

EISSN

1540-1413

Publication Date

December 2016

Volume

14

Issue

12

Start / End Page

1572 / 1611

Location

United States

Related Subject Headings

  • Thrombocythemia, Essential
  • Signal Transduction
  • Risk Assessment
  • Receptors, Thrombopoietin
  • Quality of Life
  • Primary Myelofibrosis
  • Prevalence
  • Polycythemia Vera
  • Philadelphia Chromosome
  • Oncology & Carcinogenesis